Michael P Cooreman

Title: Inventor Spotlight: Michael P. Cooreman

Introduction

Michael P. Cooreman, based in Randolph, New Jersey, is a notable inventor with a focus on pharmaceutical innovations. He holds two patents that contribute significantly to the fields of medicine and treatment methodologies.

Latest Patents

Cooreman's latest patents include a groundbreaking pharmaceutical composition for the treatment of non-alcoholic fatty liver disease (NAFLD). This invention outlines a method that utilizes a 1,4-benzoxazine compound, along with pharmaceutically acceptable carriers, to effectively treat patients suffering from NAFLD. The second patent involves methods of treating multiple myeloma using IL-17 binding molecules. This patent particularly highlights an antibody targeting human IL-17, aimed at treating both solid and hematological malignancies, showcasing his commitment to advancing cancer therapies.

Career Highlights

Over the course of his career, Cooreman has contributed to significant pharmaceutical advancements through his work at reputable companies such as Novartis AG and Novartis Pharma GmbH. His dedication to research and innovation has positioned him as a key player in the pharmaceutical industry.

Collaborations

Throughout his career, Cooreman has collaborated with notable colleagues, including Franco E. Di Padova and Kohei Kikkawa. These collaborations have fostered a conducive environment for innovation, allowing for the sharing of ideas and expertise within the scientific community.

Conclusion

Michael P. Cooreman exemplifies the spirit of innovation in the pharmaceutical field. His contributions through his patents and collaborations continue to pave the way for advancements in medical treatments, particularly in addressing complex health challenges such as non-alcoholic fatty liver disease and multiple myeloma. His work showcases the critical role inventors play in enhancing therapeutic options for patients in need.